LL-37
A host-defense peptide associated with innate immunity and tissue-response discussions.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
No major aliases are tracked for this profile yet.
No FDA label signal · 95 trials · 4190 PubMed results
What LL-37 is
LL-37 is a human antimicrobial peptide involved in innate immune signaling. In peptide-market contexts it is usually discussed in relation to host defense, inflammation, or tissue response.
Why it matters
It adds a genuine immune-facing profile to the library and helps keep the peptide catalog from collapsing into only obesity and recovery topics.
Regulatory context
LL-37 is not an FDA-approved peptide medicine for consumer use in the United States.
Practical reading note
Immune-related compounds are especially easy to overstate, so the most useful framing is what biological lane a peptide belongs to, not whether a vendor presents it as a broad health solution.